The Parkinson-control study: A 1-year randomize, double-blind trial comapring piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease

Movement Disorders

Volumn 21, Issue 4, 2006, Pages 500-509

  Castro Caldas, Alexandre ^a   Delwaide, Paul ^b   Jost, Wolfgang ^c   Merello, Marcelo ^d   Williams, Adrian ^e   Lamberti, Paolo ^f   Aguilar, Miguel ^g   Del Signore, Susanna ^h   Cesaro, Pierre ⁱ   Bueri, J ^j   Fernandez Pardal, M M ^j   Garcia, S ^j   Micheli, F ^j   Cras, P ^j   Piessens, F ^j   Tack, P ^j   Bourgeois, P ^j   De Klippel, N ^j   Van Orshoven, M ^j   Dupuis, M ^j   Cornette, M ^j   Benrabah, R ^j   Blanc, A ^j   Blard, J M ^j   Borsotti, J P ^j   Bossu, C ^j   Contis, P ^j   Danielli, A ^j   Decombe, R ^j   Der Agopian, P ^j   Dubois, B ^j   Dupuy, B ^j   Getenet, J C ^j   Girard Madoux, P ^j   Gras, P ^j   Guard, O ^j   Laverhne, L ^j   Maupetit, J ^j   Mazingue, A ^j   Merienne, M ^j   Mick, G ^j   Mihout, B ^j   Peran P ^j   Prince, P ^j   Soisson, T ^j   Tranchant, C ^j   Vespignani, H ^j   Vaunaize, J ^j   Verin, M ^j   Viallet, F ^j   Berg Mantkowski, A R ^j   Gasser, T ^j   Glass, J ^j   Hoffman, F ^j   Polzer, U ^j   Piccoli, F ^j   Bastos Lima, A ^j   Costa, C ^j   Cunha, L ^j   Ferreira, J ^j   Rosa, M ^j   Calopa, M ^j   Castro, A ^j   Chacon, J ^j   Diez Tejedor, E ^j   Gimenez Roldan, S ^j   Gonzalez Maldonado, R ^j   Kulievsky, J ^j   Linazasoro, G ^j   Lopez del Val, J ^j   Miquel, L ^j   Vela Desojo, L ^j   Vaamonde, J ^j   Critchley, P ^j   Steiger, M ^j   more..

^a CATHOLIC UNIVERSITY OF PORTUGAL   (Portugal)

^b Centre Hospitalier Regional de La Citadelle   (Belgium)

^c DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^d Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^g HOSPITAL MÚTUA DE TERRASSA   (Spain)

^h IRIS Institut de Recherches Internationales Servier   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j NONE

more..

Author keywords

Bromocriptine; Dopamine agonists; Levodopa; Parkinsons's disease; Piribedil

Indexed keywords

BROMOCRIPTINE; LEVODOPA; NEUROLEPTIC AGENT; PIRIBEDIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART ARREST; HUMAN; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; WISCONSIN CARD SORTING TEST;

ADULT; AGED; ANTIPARKINSON AGENTS; BROMOCRIPTINE; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PIRIBEDIL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646238464     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20750     Document Type: Article

References (43)

1. Lieberman A, Kupersmith M, Neophytides A, et a]. Long term efficacy of bromocriptine in Parkinson's disease. Neurology 1980; 30:518-523.
2. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995,45(Suppl. 3):S6-S12.
3. Mc Donald RJ, Horowski R. Lisuride in the treatment of parkinsonism. Eur Neurol 1983;22:240-255.
4. Poewe W. Adjuncts to levodopa therapy dopamine agonists. Neurology 1998;50(Suppl. 6):S23-S26.
5. Rascol O, Montastruc L. Role of dopaminergic agonists. Rev Neurol (Paris) 2000;156(Suppl. 2 Pt 2):98-104.
6. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(Suppl. 5):S1-S88.
7. Olanow CW, Koller WC. An algorithm for the management of Parkinson's disease treatment guidelines. Neurology 1998;50:S1-S57.
8. Hoehn MM, Elton RL. Low dosage of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985;35:199-206.
9. Teychenne PF, Bergsrud D, Elton RL, Racy A. Bromocriptine: long-term low-dose therapy in Parkinson's disease. Clin Neuropharmacol 1986;9:138-145.
10. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostrial pathways. J Pharmacol Exp Ther 1995;275:899-913.
11. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 1995;275:885-898.
12. - adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcho-linesterase inhibitors. J Pharmacol Exp Ther 2003;305:338-346.
13. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of doparmine D2-like receptor and α1/α2 adrenoreceptor. J Pharmacol Exp Ther 2002;303:805-814.
14. Smith LA, Tel BC, Jackson MJ, et al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord 2002;17:887-901.
15. Allain H, Le Coz F, Del Signore S, Chezaubernard C. Piribedil plasma levels after chronic oral administration of Piribedil Retard 50 (150 mg/ day) in parkinsonian patients. Parkinsonism Relat Disord 2001;7(Suppl.):S51-P-TU-163.
16. Bossant MJ, Bouzom F, Bodjarian N, Bonhomme C, Bonnet AM. 24-hour pharmacokinetic profile of piribedil during chronic oral administration in de novo parkinsonian patients treated by monotherapy. Eur J Neurol 2003;10(Suppl. 1):166(P2148).
17. Truelle JL, Chanelet J, Bastard J, Six P, Emile J. Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (authors transl). Nouv Presse Med 1977;33:2987-2990.
18. Callaghan N, Fitzpatrick E, O'Mahony JB. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa. Acta Neurol Scand 1975;52:179-186.
19. Mentenopoulos G, Katsarou G, Bostanjopoulou S, Logothetis J. Piribedil therapy in Parkinson's disease. Use of the drug in the retard form. Clin Neuropharmacol 1989;12:23-28.
20. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study. J Neurol 1992;239(Suppl. 1):S28-S34.
21. Kwiecinski H, Fedorova N, Takats A, Ruzicka E, Jamrozik Z, Del Signore S. A multicenter trial of Piribedil as early adjunct treatment for Parkinson's disease: Piribedil International Study Group (PISG). Neurology 2002;58(Suppl. 3):A163.
22. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Mov Disord 2003;18:418-425.
23. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
24. Rascol O, Gershanik O, Blin O, Ferreira J, Bodjarian N, Lees A. Piribedil efficacy in monotherapy (150-300 mg/day) in de novo parkinsonian patients: a 6-month intermediate analysis of the 2-year Parkinson-REGAIN study. Neurology 2004;62(Suppl. 5): A399.
25. Lees A, Gershanik O, Blin O, Behari M, Otero E, Ferreira J, Aguilar M, Kies B, Castro-Caldas A, Bodjarian N, Rascol O. Piribedil efficacy in monotherapy (150-300 mg/day) in de novo Parkinsonian patients: a 6-month planned intermediate analysis of the 2-year Parkinson-REGAIN study. Mov Disord 2004; 19(Suppl. 9):P603.
26. Hoehn MM, Yahr MD. Parkinson: onset progression and mortality. Neurology 1967;17:427-442.
27. Fahn S, Elton RL and Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, editors. Recent developments in Parkinson's disease. Vol. 2. Florham Park: MacMillan Health Care Information; 1987. p 153-163.
28. CPMP. Note for guidance on clinical investigation of medicinal products in the treatment of Parkinson's disease. London, EMEA; CPMP/EWP/563/95; December 1998.
29. CPMP. Points to consider on switching between superiority and non-inferiority. London, EMEA; CPMP/EWP/482/99; July 2000.
30. CPMP. Point to consider on adjustment for covariates. London, EMEA: CPMP/ EWP/2863/99; May 2003.
31. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm. 2002;109:489-502.
32. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3 year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 study group. Neurology 1999; 53:364-370.
33. Guttman M and the International Pramipexole-Bromocriptine Study group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997;49:1060-1065.
34. LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983;8: 1009-1014.
35. Pezzoli G, Martignoni E, Pacchetti C, et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology 1995;3(Suppl. 3):S22-S27.
36. Mizuno Y, Kondo T, Narabayachi H. Pergolide in the treatment of Parkinson's disease. Neurology. 1995;45(Suppl. 3):S13-S21.
37. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson's disease rating scale motor examination. Mov Disord 1994;1:89-91.
38. Pillon B, Boller F, Levy R, Dubois B. Cognitive deficits and dementia in Parkinson's disease. In: Boller F, Grafman J, editors. Handbook of Neuropsychology. Vol. 6. Aging and dementia. Amsterdam: Elsevier; 2001. p 311-371.
39. Gotham AM, Brown RG, Mardsen CD. Frontal cognitive function in patients with Parkinson's diseasle on and off levodopa. Brain 1988;111(Pt 2):299-321.
40. Brown RG, Marsden CD. Internal versus external oues and the control of attention in Parkinson's disease. Brain 1988;111(pt2): 323-345.
41. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8.
42. Woodward TS, Bub DN, Hunter MA. Task switching deficits associated with Parkinson's disease reflect depleted attentional resources. Neuropsychologia 2002;40:1948-1955.
43. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351: 2509-2518.